Dr Bhavjit Kaur and Sue Thomson discuss the rising patient demand for dyschromia treatments.
The global pigmentation market is projected to soar to US $10.22 billion (£8,229 billion) by 2026, demonstrating a strong compound annual growth rate (CAGR) of 8.4%.1 This surge highlights the increasing demand for pigmentation treatments and raises a crucial question: is the UK medical aesthetics sector prepared to meet this rising demand both clinically and commercially?
Dyschromia
Dyschromia refers to abnormal or uneven skin pigmentation, where the skin tone deviates from its usual colour. It can appear as either hyperpigmentation (dark spots or patches) or hypopigmentation (light spots or patches), or sometimes a combination of both.2
In cases of hyperpigmentation – such as melasma or post-inflammatory hyperpigmentation (PIH) – the production of melanin increases in response to triggers like UV exposure, hormonal changes or inflammation. Interestingly, the number of melanocytes (the…
